Introduction
Choriocarcinoma is a highly invasive tumor consisting of markedly anaplastic trophoblasts totally lacking residual villous structures. However, little is known of the molecular mechanisms underlying the development of this tumor. The tumor may originate from the trophoblasts of any conception. Although malignant complications infrequently occur after abortion, or after an apparently normal live birth, the risk of choriocarcinoma associated with a complete mole is 2000 to 4000 times greater than that of an apparently normal live birth (Park, 1971) . A complete hydatidiform mole, which is characterized by grossly swollen villi in the absence of a fetus, is androgenetic in origin. The entire genome of the molar conceptus is paternally derived (Kajii and Ohama, 1977; Wake et al., 1978a, b; Jacobs et al., 1981) . The majority of moles results from fertilization of an egg devoid of nuclei (an empty egg) by a haploid sperm. The paternally derived haploid set then duplicates without cytokinesis and restores diploidy (Jacobs et al., 1981; Yamashita et al., 1979) . Invariably, this class of moles has a 46, XX karyotype and is completely homozygous for genetic markers. Fertilization of an empty egg by two spermatozoa is responsible for the remaining cases (Ohama et al., 1981; Pattillo et al., 1981; Surti et al., 1979) . This mole is heterozygous at some genetic loci but homozygous at others. It is assumed that genetic features seen in complete moles associate with their potential to progress to choriocarcinomas. The monoallelic contribution would render a certain gene susceptible to functional inactivation by`one hit' kinetics. Alternatively, uniparental transmission of genes that are subject to parental imprinting in human would impair their regulation (Scable et al., 1989) . Thus, some tumor suppressor genes that are inactivated by one of the two previously mentioned mechanisms would play an important role for the high propensity to malignancy seen in complete moles. However, a unique characteristic of the mole has prevented exploration of genetic mechanisms associated with choriocarcinoma development. Many tumor suppressor genes are inactivated by intragenic mutations in one allele, accompanied by the loss of a chromosomal region containing the remaining allele, termed loss of heterozygosity (Cavanee et al., 1983; Vogelstein et al., 1989; Yokota et al., 1987) . Mapping such deleted regions has been done to identify sequences involved in malignancies. However, the method is not suitable for disclosing the genetic alternations in choriocarcinomas because monoallelic contribution in the complete mole and its putative transformant should mask the allelic loss. To resolve this diculty, we ®rst identi®ed a speci®c human chromosome on which putative tumor suppressor gene is located, using microcell-mediated chromosome transfer. A transfer of chromosome 7 via microcell fusion clearly suppressed tumorigenicity and in vitro growth properties of choriocarcinoma cells. Then, using a panel of microsatellite markers we found a homozygous deletion in the chromosome 7p12-7q11.23 region that was frequent in surgically removed choriocarcinoma tissues and cell lines. These ®ndings should help positional cloning of the target tumor suppressor gene(s) involved in choriocarcinoma development.
Results

A Single chromosome transfer into choriocarcinoma cells
We introduced individual human chromosomes into CC1 choriocarcinoma cells via microcell fusion to identify the chromosome carrying putative tumor suppressor gene(s). The karyotype of parent CC1 cells was unstable and the total number of chromosomes ranged from 80 to 95 with 25 ± 30 rearranged marker chromosomes. In two to three successive fusion experiments with microcells prepared from mouse cells with dierent human chromosome (eq A9 (neo1), A9 (neo2), A9 (neo6), A9 (neo7), A9 (neo9), and A9 (neo11) cells), 2 to 8 G418 resistant CC1 microcell-hybrids were randomly isolated, propagated in the presence of G418 for further analyses, and karyotyped. These clones were then examined for an excess number of transferred chromosomes. As the parental CC1 cells contained complicated karyotypes, we could not con®rm by karyotypic analysis either the presence or absence of the transferred chromosome. Thus, we carried out chromosomal¯uorescence in situ hybridization (FISH), using the pSV2-neo as a probe to demonstrate the successful transfer of the donor chromosome into CC1 cells. The introduced chromosomes tagged with the pSV2 neo gene were identi®ed in each microcell-hybrid clone (Figure 1 ). The chromosomal location of signals corresponded to the integration site of the pSV2-neo gene observed (Koi et al., 1989) .
We evaluated tumorigenicity and in vitro transformed phenotypes in these microcell-hybrids and made comparisons with the parental CC1 cells (Table  1) . CC1 cells formed progressively growing tumors with 100% tumor-take incidence following the subcutaneous inoculation of 1610 7 cells into nude mice. An average number of days until the long axis of the tumor to reach 10 mm (PMD) was 26 days. All of the microcell-hybrid clones containing a single chromosome 1, 2, 6, 9 and 11 were also highly tumorigenic; the tumor-take incidence and the PMD ranged from 83 to 100%, and from 16 to 34 days in these clones. The dierence was not statistically signi®cant between the parent CC1 cells and the microcell-hybrids.
This was in sharp contrast with the suppression of tumorigenic potentials in microcell-hybrid clones with a transferred chromosome 7. We obtained 4 microcellhybrid clones that contained the transferred chromosome 7. Complete suppression of tumorigenicity was observed in one clone (#7-1), from which no tumor was produced for up to 100 days following inoculation of 1610 7 cells. Tumorigenic potentials were partially suppressed in the remaining 3 clones (#7-2, #7-3 and #7-4). Reduced tumor-take incidence (18 to 59%) and prolonged PMD (47 to more than 80 days) were demonstrated in these clones. We obtained cells (tumorigenic revertants) from tumors produced by the inoculation of these clones to determine factors that may explain the variation in tumorigenic potential among the chromosome 7 transferred microcell-hybrid clones. These revertants were highly tumorigenic, producing progressively growing tumors with 75 ± 100% tumor-take incidence. The microcell-hybrid clones contained three to four copies of chromosome 7, whereas two or three copies of chromosome 7 were observed in the parent CC1 cells (Figure 1 ). However, reduction of a single copy of chromosome 7 seemed apparent in three tumorigenic revertant cells, compared to the copy number of chromosome 7 in the microcellhybrid clones (date not shown).
MspI-digested DNA from various cells were hybridized with a 32 P-labeled ERV3 subclone (pHP1.7) which showed a 3.3 kb restriction fragment in the parent CC1 cells and 2.8 kb restriction fragment in the donor A9 (neo7) cells (Figure 2 ). Both bands were observed in MspI-digested cellular DNAs obtained from 4 microcell-hybrids with the transferred chromosome 7 as well as from their tumorigenic revertants. These ®ndings suggest that the tumorigenic revertants retained the donor chromosome's ERV3 locus and that this region is not involved in the tumorigenic suppression.
In vitro growth properties of the microcell-hybrids that contained chromosomes 1, 2, 6, 9 or 11 were similar to those of the parent CC1 cells (Table 1) . However, signi®cant prolongation of population doubling time and suppression of soft agar growth eciency were demonstrated in the microcell-hybrid clones that contained a transferred chromosome 7. Morphology of the microcell-hybrid cells was remarkably altered (Figure 3) .
In order to test whether chromosome 7 aected the tumorigenicity of other choriocarcinoma cells, we transferred chromosome 7 into another choriocarcinoma cell line (JEG-3). All clones were aected by this chromosome. One clone showed a complete loss of tumorigenic potential, and three other clones showed a reduction in the tumor-take incidence and an increased latency for tumor growth from 23 days for the parental cells to 58 ± 217 days for clones with an introduced chromosome 7. The growth of these chromosome 7 transferred microcell-hybrids with JEG3 was markedly reduced as was observed with CC1 cells (data not shown). These results indicated that a single human chromosome 7 derived from normal ®broblasts had the potential to suppress or to modulate the tumorigenicity and the in vitro growth properties of human choriocarcinoma cells. This potential was clearly not shared by the human chromosome examined here. Thus the observation is compatible with the idea that chromosome 7 carries putative tumor suppressor gene(s) that negatively regulate choriocarcinoma cell growth.
H-plk sequences not involved in tumorigenic suppression
A human ERV3 provirus that locates on human chromosome 7 is abundantly expressed in the placental chorionic villi throughout gestation. Cohen et al., (1988) and Kato et al., (1988) demonstrated the complete absence of ERV3 transcription in choriocarcinomas or invasive moles. There are three envcontaining ERV3 mRNAs of 9, 7.3 and 3.5 kb. Although the 3.5 kb mRNA contains only proviral sequences, the 9 and 7.3 kb mRNAs extend to a splice donor site downstream from the provirus (Kato et al., 1987) . As a result, these involve nonviral genomic sequences at their 3'-ends due to alternative splicing. The transcripts encode a Kruppel-related zinc ®nger protein (H-plk). The structural homology with Drosophila Kruppel that is essential for normal embryonic development suggests a putative function as a transcription factor (Kato et al., 1990; Bellefroid et al., 1989) . The failure to detect 9 and 7.3 kb transcripts in addition to 3.5 kb isolated from choriocarcinomas led to the speculation that the absence of H-plk protein may be the primary defect associated with choriocarcinoma development (Kato et al., 1990) . This hypothesis is compatible with our results that the chromosome 7 introduced into choriocarcinoma cells can negatively regulate cell growth. We then asked whether the H-plk encoded from the transferred chromosome 7 is responsible for modulation of tumorigenicity and in vitro growth properties of choriocarcinoma cells. As a control experiment, Northern blots of 8 placental RNAs using the ERV3 probe detected 9, 7.3 and 3.5 kb mRNAs that were characteristic of ERV3 transcription. As expected, the probe failed to detect these transcripts in RNAs obtained from each 4 choriocarcinoma tissues and cell lines ( Figure 4 ). Recovery of 3.5 kb mRNA expression was demonstrated in the microcell-hybrid containing chromosome 7. This contrasted with the complete abrogation of 9 and 7.3 kb mRNAs transcription in the hybrids. These results were con®rmed using RT-PCR (Figure 4b ). Primer pairs were designed for the ERV3 env region and the H-plk open reading frame (ORF), respectively ( Figure 4c ). The PCR of cDNAs obtained from 8 placentae ampli®ed 420 and 400 bp fragments that were compatible with the size predicted from the ERV3 env and H-plk ORF gene sequences. Either trace levels or no PCR products was detectable in 8 choriocarcinomas. The ampli®ed cDNAs obtained from the microcell-hybrids containing chromosome 7 showed no 400 bp fragment encoded from H-plk gene sequences, whereas the 420 bp from ERV3 env region was readily detected. As a result, transfer of a chromosome 7 into CC1 choriocarcinoma cells did not lead to the recovery of H-plk transcription. It is unlikely that the deletion of a transferred chromosome 7 from the hybrids corresponded to the absence of Hplk transcription because the ERV3 cDNA was readily ampli®ed. Thus, H-plk transcription apparently did not contribute to the potential of a chromosome 7 to suppress tumorigenicity and in vitro growth properties of CC1 cells.
Homozygous deletion of chromosome 7
Because DNA samples from the preceding complete mole were not available, we used constitutional DNAs from the patient and her sexual partner as paired samples of choriocarcinoma. Despite the rarity of this tumor, we were able to collect 14 surgically resected choriocarcinoma samples that were sequel to the complete mole. We used 25 PCR-ampli®ed microsatellite repeats to screen the 14 choriocarcinomas for rearrangements or deletions on chromosome 7 ( Figure  5 ). Choriocarcinomas, like many solid tumors, contain expanded necrotic tissues and various numbers of nonneoplastic cells that could mask genomic alterations occurring within the neoplastic tumor cell population. A cryostat sectioning method for physically fractioning such tumors to enrich for neoplastic cells was used. DNAs from 8 control placentae revealed intact microsatellite loci by PCR ampli®cation of the marker fragments using published (Tsui, 1995; Weissenbach et al., 1992) forward and reverse primers (data not shown). In turn, electrophoresis of PCR products run on a 6% denaturing polyacrylamide gel demonstrated biallelic loss of part of chromosome 7 in choriocarcinoma samples. Con®rmation of homozygous deletions was made by multiplex PCR ampli®cation of two independent STS markers. One STS content could not be ampli®ed while ampli®cation of the other did occur in these choriocarcinoma specimens. The results were further con®rmed in parallel ampli®cations of DNAs derived from leukocytes for the patients and partners. The STS contents were absent from tumor DNA samples but present in constitutional DNA samples from the patients and their partners, thereby confirming the homozygous deletion. Homozygous deletions occurred in at least one locus on chromosome 7, in 10 of 14 tumors (71%). The incidence of homozygous deletion was unexpectedly high and thus eight choriocarcinoma cell lines were further examined to con®rm the involvement of a homozygous deletion on chromosome 7 in choriocarcinomas. CC2 choriocarcinoma cells developed from a complete mole whereas the remaining 7 cells were derived from a normal fertilization product. We did not obtain DNAs from the patients or their partners. All eight cell lines lost a particular region on chromosome 7 biallelically, which is signi®cantly higher than the incidence of homo- Figure 4 (a) Northern blots using ERV3-env as a probe. Placenta expressed abundant 9, 7.3 and 3.5 kb mRNAs. The probe failed to detect these transcripts in 8 choriocarcinomas. However, 3.5 kb transcripts were detectable in the nontumorigenic microcell hybrid containing a chromosome 7 (CC1#7). (b) Expression analyses of ERV3 and H-plk using RT-PCR. The PCR of cDNA from placenta ampli®ed both 420 bp ERV3 env and the 400 bp H-plk fragments, whereas any fragments were undetectable in 8 choriocarcinomas. The 420 bp fragment that was compatible with ERV3 env was ampli®ed, but the 400 bp H-plk fragment was undetectable in the microcell hybrid containing a chromosome 7(CC1#7) that had lost tumorigenicity. Samples loaded on the gel are indicated in the above of the ®gure. Arrows on the Northern blot indicate transcript size. Arrows in the lower ®gure indicates 420 bp (ERV3 env) and 400 bp (H-plk) fragments ampli®ed by RT-PCR. Control GAPDH cDNAs were ampli®ed in all samples (data not shown). (c) A map of ERV3 and H-plk gene. Position of the pHP 1.7 probe is indicated. The primer pairs for ERV3 env and H-plk ORF are indicated by arrows. The primer pairs were designed for the speci®cally ampli®ed region of H-plk ORF (Ohnishi et al., 1996; Kastury et al., 1996) . In summary, 18 choriocarcinomas had interstitial deletions on chromosome 7. Overlapping deletions of the samples showing interstitial losses indicated that the smallest common deleted region was enclosed between D7S520 and D7S663 (7p12-7q11.23). The most frequent deletion among 25 markers was observed with D7S502 and D7S482. In addition, the ERV3 proviral genome that was also mapped to the 7p12-7q11.23 was lost in 6 or 14 tumor samples, whereas all 8 choriocarcinoma cell lines were retained ( Figure 6 ). None of the samples studied showed deletions at any other microsatellite loci with even the smallest common deleted region retaining intact. These results were con®rmed by repeated multiplex PCR reactions followed by electrophoresis on a 2% agarose X gel. By analogy to deletions found in various malignancies, the homozygous deletions observed here might possibly include a tumor suppressor gene, the loss or inactivation of which would play a role in initiation or progression of choriocarcinoma.
Discussion
We have adopted a new strategy to search for the locus of tumor suppressor gene(s) associated with choriocarcinoma. This was necessary because tumor samples are scarce and the contribution that is characteristic of the preceding complete mole is monoallelic. To maximize validity of the genetic investigation, we directed attention to modulation of tumorigenicity and in vitro growth properties of choriocarcinoma cells by introducing a normal chromosome via microcell fusion. The expression of genes locating on the transferred chromosome is regulated by the physiological control of chromosomal sequences. Thus, microcell-mediated chromosome transfer procedures have been used successfully to introduce speci®c chromosomes to test for the suppression of tumorigenic phenotypes of cell lines derived from various human malignancies (Stanbridge, 1988; Yamada et al., 1990; Zenklusen et al., 1994a,b,c; Oshimura et al., 1990; Saxon et al., 1986; Tanaka et al., 1991; Porteous et al., 1989; Weissman et al., 1987; Conway et al., 1992) . We generated and characterized microcellhybrids containing dierent individual chromosomes. The tumorigenicity and in vitro growth of the microcell-hybrids with transferred chromosomes 1, 2, The absence of any PCR products at D7S663 locus was evident in case 8 choriocarcinomas. However, ampli®ed fragments were evident in constitutive DNAs obtained from the case 8 husband and the patient. Similarly, the PCR product was undetactable in DNAs from case 4, 6, 7, choriocarcinomas and Bewo, CC1 and JAR cells. DNA fragments at D7S520 failed to be ampli®ed in case 4 and Bewo and CC1 cells. Both fragments at D7S663 and D7S520 were readily ampli®ed in DNAs from cases 5, 10 and 13 choriocarcinoma tissues, and NJG, CC3 and NUC-1 cells. The homozygous deletion was con®rmed in repeated multiplex PCR. The homozygous deletion shown by electrophoresis on 7M denaturing acrylamide gel (upper) were further con®rmed by electrophoresis on 2% agarose X gel (lower) Figure 6 Map of homozygous deletions on chromosome 7. DNA samples from 14 choriocarcinoma tissues and 8 choriocarcinoma cell lines were examined for biallelic losses of STS markers located on chromosome 7. Closed squares represent homozygous deletions but blanked squares mean the retention of a single or both alleles. Hatched squares mean that the locus indicated was not tested. The physical locations of STS markers are based on data described tentatively by Tsui, 1995; Ohnishi et al., 1996) . The smallest common deleted region is enclosed between D7S520 and D7S663 (7p12-7q11.23) 6, 9 or 11 showed that the introduction of a human chromosome into a choriocarcinoma cell line did not aect its tumorigenicity or proliferative potential to any signi®cant extent. However, all 4 microcell-hybrid clones that contained a transferred chromosome 7 were clearly suppressed both in tumorigenicity and particular properties of in vitro growth. In addition, tumorigenic revertants obtained from these microcellhybrid clones lost major parts of transferred chromosome 7 even when the donor chromosome's ERV3 locus was retained. The consistency between these two sets of data led to the notion that a putative tumor suppressor gene(s) probably locates on chromosome 7. Some gene products of murine endogenous retroviruses, but not intact viruses, are involved in the pathogenesis of malignant diseases (Martin et al., 1981) . Among them, a human ERV3 provirus and its related H-plk sequences are localized on chromosome 7 (O'Connell et al., 1984; Bellefroid et al., 1992) . The alternative splicing produces the transcripts that encode cellular H-plk sequences (Kato et al., 1990; Bellefroid et al., 1989) .
Extinction of H-plk transcription has been suggested as the primary defect involved in choriocarcinoma development. However, the absence of H-plk transcription in nontumorigenic microcell-hybrids containing an introduced chromosome 7 excluded the H-plk in choriocarcinoma suppression. ERV3 itself has a long ORF in the env region (O'Connell et al., 1984) . Thus, the present result does not completely exclude the involvement of ERV3 env region in choriocarcinoma, as the possibility exists, although unlikely, that transcript from the donor chromosome's ERV3 gene was present in the nontumorigenic microcell-hybrids but absent in their tumorigenic revertants. Preferential localization of ERV3 mRNAs in syncytiotrophoblasts contributes to the observed high expression in placenta (Boyd et al., 1993; Venables et al., 1995) . This expression correlates with the fusion process itself. The lack of ERV3 transcription in choriocarcinoma most probably corresponds to the scarcity of such fused cells because choriocarcinoma is predominantly composed of intermediate trophoblasts and cytotrophoblasts. This is compatible with the possibility that, outside of ERV3 and its related H-plk gene loci, at least one target tumor suppressor gene is localized on chromosome 7.
We have in fact obtained evidence to de®ne the critical region that is lost biallelically in choriocarcinomas by using a panel of microsatellite markers located on chromosome 7. It is probable that some genetic alterations that occur do not aect cancer cell growth but represent errors that become ®xed during clonal expansion. However, the unexpectedly high incidence and the involvement of more than one contiguous marker in the deleted region strongly suggest that the homozygous deletion detected here is important and de®ne locus of the putative tumor suppressor gene. Although complete data are not available, the occurrence of deletions involving both alleles is infrequent. Because of the total loss of particular genetic information, the cellular eect of most homozygous deletions is assumed to be deleterious. Indeed, the homozygous deletions reported to date are relatively small and have been noted only in a few malignancies (Ohnishi et al., 1996; Kastury et al., 1996; Boyd et al., 1993; Schutte et al., 1995; Roche et al., 1996; Decker et al., 1996) . The monoallelic contribution could contribute to the high incidence of homozygous deletions in choriocarcinomas. However, all of the seven choriocarcinoma cell lines that developed from normal placentae also contained a deletion of biparental alleles in this critical region. A possible analogous situation exists with the p16 tumor suppressor gene, wherein a variety of human malignancies have a homozygous deletion (Ohnishi et al., 1996) . Interstitial deletions may represent the main mechanism to inactivate the putative tumor suppressor gene on chromosome 7. If such is indeed the case, additional cases of choriocarcinoma harboring intragenic mutations in this aected region may have gone undetected.
The homozygous deletions identi®ed here maps to chromosome 7p12-7q11.23. The region that is proximal to the centromere is bordered by markers D7S520 and D7S663. Although a number of microsatellite markers have been mapped to the region, their precise location remains to be determined. Thus, determination of the physical order of markers is necessary to accurately determine the deletion pattern. The presence of tumor suppressor gene on chromosome 7 has been suggested for various cancers. Deletions in 7q with breakpoints varying from q11 to q34 have been described in esophageal and gastric cancers (Kuniyasu et al., 1994; Atkin and Baker, 1993) . Recent investigations using VNTR or microsatellite markers described high frequencies of allelic deletion in 7q in colon (Zenklusen et al., 1995) , head and neck (Speicher et al., 1995) , gastric (Kuniyasu et al., 1994) , pancreatic (Achille et al., 1996) , prostate (Atkin and Baker, 1993; Zenklusen et al., 1994c) , ovary (Atkin and Baker, 1993), breast cancers (Zenklusen et al., 1994a; Bieche et al., 1992) leiomyosarcoma (Sreekantia, 1993) , and non tumorigenic immortal human cell line SUSM-1 (Ogata et al., 1993) . However, the commonly deleted region in these cancers is localized at 7q31.1-32, which is more distal than the aected region detected here. Ogata et al. (1993) showed that cellular senescence of 2 nontumorigenic human immortalized-®broblast cell lines was overcome by transfer of chromosome 7. However, it remains to be determined whether the cellular senescence gene and the tumor suppressive gene in choriocarcinomas are causally related to the same gene on chromosome 7. Homozygous deletion detected in the present study should provide an invaluable tool for positional cloning of the target tumor suppressor gene at 7p12-7q11.23. A YAC library construction is now in progress for the cloning of this putative tumor suppressor gene.
Materials and methods
Specimens and cells
Specimens: Eight normal placental tissues were obtained at delivery. Fourteen choriocarcinoma tissues, all of which were sequel to the complete mole, were removed surgically. Each specimen was immediately frozen in liquid nitrogen and stored at 7708C. A section made from each carcinoma sample was stained with hematoxylin/eosin, following microscopic con®rmation by a registered pathologist.
Cells lines: The choriocarcinoma cell lines, Bewo, CC1, CC2, CC3, NUC-1, JEG3, JAR and NJG were kindly provided by Drs S Sekiya, (Chiba Univ.), K Tanaka, (Niigata Univ.), S Nozawa, (Keio Univ.), Y Tomoda, (Nagoya Univ.), and K Suzumori (Nagoya City Univ.). A CC2 cell line was derived from a complete mole whereas the other choriocarcinoma cell lines were established from choriocarcinomas developed from an apparently normal live birth (Bewo, NUC1, JEG3, JAR, NJG), stillbirth (CC3) or abortion (CC1). Growth properties and tumorigenicity of these cells have been documented (Pattillo and Gey, 1968; Pattillo et al., 1971; Suzumori et al., 1983; Kohler and Bridson, 1971; Sugiura et al., 1988; Nozawa et al., 1987) . These cell lines were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) or F12 supplemented with 10% fetal bovine serum (FBS) at 378 C in a humidi®ed 5% CO 2 atmosphere. The absence of micoplasma was con®rmed in the cell lines before they were subjected to the following experiments.
Chromosome transfer via microcell fusion
Mouse A9 cells carrying a signal copy of normal human chromosome tagged with the neomycin phosphotransferase gene (pSV2-neo) were used as donor line for microcell mediated chromosome transfer. A9 (neo 1), A9 (neo 2), A9 (neo 6), A9 (neo 7), A9 (neo 9) and A9 (neo 11) retained normal human chromosome 1, 2, 6, 7, 9 and 11, respectively. The details of the procedure have been described previously (Koi et al., 1989) . A9 cell clones containing a human chromosome were incubated with 0.05 mg/ml colcemid in DMEM supplemented with 20% FBS for 48 h. The culture¯asks were then ®lled with medium containing 10 mg/ml cytochalasin B and centrifuged in a Sorvall GSA ®xed-angle rotor at 10 000 g for 60 min at 348C. The obtained microcells were suspended in serum-free medium and puri®ed by sequential polycarbonate ®ltration (Nucleopore). The puri®ed microcells were overlaid and attached to recipient CC1 cells with 100 mg/ml phytohemagglutinin. Microcell fusion were done by placing 50% polyethylene glycol 1500 (Boehringer Mannheim, Germany) solution over the cell layer for 1 min. After 24 h incubation in DMEM containing 10% FBS, G418 at 400 mg/ml was added. G418 resistant colonies were isolated after the 21 ± 60 days of selection.
Chromosomal¯uorescence in situ hybridization
The hybridization protocol followed that of Cherif et al. (1989) , with slight modi®cations. Metaphase cells on glass slides were prepared according to standard procedures, denatured in 70% formamide/26SSC at 708C for 2 min, then dehydrated through cold 70, 90, and 100% ethanol for 5 min each. The probe pSV2neo was labeled by nick translation with biotin-16-dUTP for 1.5 h at 158C. The labeled probe was puri®ed by ethanol precipitation, dissolved in 20 ml of 100% formamide, and denatured at 758C for 10 min. Twenty microliters of hybridization solution (bovine serum albumin (BSA; 20 mg/ml), 106SSC, and 50% dextran sulfate, 1 : 2 : 2) and 20 ml of labeled probe DNA were placed in an Eppendorf tube. The solution (20 ml/slide) was placed drop-wise on the denatured chromosomes, covered with Para®lm, and incubated overnight at 378C in a humidi®ed chamber. After hybridization, the slides were washed in 50% formamide/26SSC (378C), and 16SSC for 15 min each and once in 46SSC for 5 min. The slides were immersed in 70 ml of¯uorescein isothiocynate (FITC) -avidin (5 mg/ml in 46SSC with 1% BSA) and incubated at 378C for 45 min, then washed with 46SSC, 46SSC containing 0.1%. Triton X-100, and 46SSC for 5 min each. The slides were incubated with 70 ml of biotinylated anti-avidin (5 mg/ml in 46SSC with 1% BAS) at 378C for 60 min.
After washing, another layer of FITC-avidin was added for ampli®cation. The slides were washed and mounted in antifade solution [1% diazabicyclo-octane in glycerol with 10% phosphate-buered saline] containing 0.75 mg/ml of propidium iodide. Signals were observed and photographed under a¯uorescence microscope (Nikon) with Ektachrome ®lm (Kodak, ASA100).
Evaluation of tumorigenicity and in vitro transformed properties
Tumorigenicity in vivo was evaluated following the dorsal subcutaneous inoculation of 1610 7 cells per site in 4-to 9-week-old athymic ICR nu/nu mice. The animals were observed for 100 days. Both tumor-take incidence and the period that required for a tumor to grow to a maximum diameter of 10 mm (PMD) were recorded. For calculation of the number of cell population doublings, cells from the parent CC1 and microcell-hybrids were plated in triplicate in DMEM containing 10% FBS on 24-well dishes at a density of 5610 4 cells. Media were changed at 3-day intervals, and the numbers of cells was counted for the following 1 ± 10 days. For evaluation of anchorage independent growth ability, a single cell suspension of parent CC1 cells and microcell hybrids (1610 3 ) in 0.3% agar was overlaid on 0.5% basal agar, followed by 4 weeks of observation. Colonies with a diameter of 4100 mm were scored.
DNA and RNA isolation
Genomic DNA was isolated from placentae and choriocarcinoma tissues, and choriocarcinoma cell lines by proteinase K and SDS treatment followed by phenol and chloroform extraction (Sambrook et al., 1982) . Tumor samples were puri®ed by microdissection of cryostat sections of tissues to minimize contamination of normal tissues. RNA was isolated by acid-guanidine method (Sambrook et al., 1982) and was treated with RNase-free DNase, extracted with phenol/chloroform and precipitated with ethanol.
Southern hybridization
Genomic DNA from the parent CC1, microcell-hybrids containing chromosome 7 and their tumorigenic revertants were isolated by lysis in 10 mM Tris-HCl (pH 7.5)/10 mM EDTA/2% SDS with proteinase K at 200 mg/ml, incubated for 3 h at 508C, puri®ed by phenol and chloroform extraction, and precipitated with ethanol. Southern blot analysis was carried out using restriction fragments labeled to high speci®c activity (Rediprime Kit, Amersham, UK) as a hybridization probe. The pHP 1.7 plasmid DNA which is located in chromosome 7 was used for the detection of the transferred chromosome 7 (O'Connell et al., 1984) .
Northern blot and reverse transcriptase polymerase chain reaction (RT-PCR)
Northern blot hybridization analysis was performed with poly(A)+ RNA. Five micrograms of poly(A)+RNA were electrophoretically separated on 1% agarose containing 15% formaldehyde, transferred to a nylon membrane, Hybond-N + (Amersham, UK), and then hybridized with the 32 P-labeled pHP 1.7 probe speci®c to the env region of ERV3. Autoradiographic evaluation of the gene expression was done by the BAS1000 imaging plate system (Fuji Film, Japan).
RT-PCR was performed using 4 mg of total RNA with Tth polymerase (Perkin Elmer, USA) according to the manufacturer's protocol. ERV3 and H-plk cDNAs were ampli®ed with primers designed for the env-region of ERV3 gene and for the speci®c region of open reading frame of H-plk gene (Figure 2c ). The primer pairs were 5'CTTGGTACCAACTTGAAGC-3' (ERV3-1) and 5'-CCC-CTGCAGTTTCATTGGTGGT-3' (ERV3-2), and 5'-GAGC-CTTTAACTGGTCCTC-3' (H-plk-1) and 5'-TTGTGGG-GATTCTCTCCAG-3' (H-plk-2), respectively. PCR conditions involved an initial denaturation for 5 min at 948C, followed by 30 cycles of 948C for 1 min, 558C for 1 min, 728C for 2 min, with ®nal 7 min incubation at 728C. PCR products were electrophoresed on 2% agarose X (Nippongene, Japan) gels and stained with ethidium bromide. GAPDH (Arcari et al., 1984) cDNA was also ampli®ed with the primer pairs as a control.
PCR ampli®cation of STS and ERV3
To detect deleted regions on chromosome 7, speci®c sequenced tag site (STS) primers purchased from Research Genetics (USA) were used. Locus and marker name in parenthesis are listed below; D7S531 (AFM254yc9), D7S513 (AFM217yc5), IL-6, D7S484 (AFM087yd11), TCRG, GCPS, EGF-R (SAVH3), D7S519 (AFM238vb12), D7S494 (AFM165zf4), D7S499 (AFM19lxh6), D7S520 (AFM240ve9), D7S502 (AFM199vh8), D7S482 (AFM070ye1), D7S663 (AFM280zc5), D7S639 (AFM220ya3), D7S645 (AFM238zc9), ELN, D7S669 (AFM286xf9), D7S489 (AFM136xe3), D7S524 (AFM248ta5), D7S486 (AFM098xg9), D7S483 (AFM074xg5) and D7S594 (AFM254cy9). D7S482, 502, 520, 663 were reported to be assigned to the same chromosomal position (Tsui, 1995) .
ERV3 sequence was ampli®ed with the same primers used in the RT-PCR. Simultaneous PCR ampli®cation of 2 ± 3 STSs was performed as recommended by the manufacturer (Research Genetics, USA) but with some modi®cations (Weissenbach et al., 1992) . PCR products were labeled by incorporation of [a-32 P] dCTP during thermo-cycle reactions. After denaturation by heating at 958C, the products were run on 6% denaturing polyacrylamide gel containing 7 M urea. Then, the gel was exposed to an imaging plate, and bands were detected using the BAS 1000 system and an imaging plate (Fujix, Japan). When a homozygous deletion was suggested by the total loss of alleles in the tumor DNA, further multiple PCR reaction was performed with two or three independent primer pairs in the same tube without radio-labeling. The ampli®ed products were electrophoresed on a 2% agarose X gel, followed by Southern blotting using a-32 P-dCTP labeled probes that were extracted from the agarose containing the ampli®ed DNA fragment of STSs.
Genbank Accession Numbers
ERV3 (Genbank Accession No. M12140) H-plk (Genbank Accession No. M55422). 
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